# The Column Group

> The Column Group is a VC fund backing Biotechnology and Health Care. See 152 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: San Francisco, United States
- Total investments: 152
- Last investment: Jun 2026
- Lead investor: 37%
- Last updated: Aug 2026
- LinkedIn: http://www.linkedin.com/company/the-column-group
- Website: https://www.thecolumngroup.com/

The Column Group is a venture capital firm dedicated to creating the next generation of biotechnology companies. They manage over $4 billion in assets and focus on building companies with groundbreaking scientific platforms that have the potential to deliver significant new therapies for unmet medical needs. TCG takes a long-term approach, aimingto develop companies capable of generating multiple product opportunities rather than focusing on quick exits.

## Contacts

5 contacts available for The Column Group. Shizune tracks 18 team members at The Column Group. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/the-column-group?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Series A | $15M–$102M |
| Series B | $22M–$120M |
| Series C | $37M–$120M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 46 | 30% |
| Health Care | 31 | 20% |
| Therapeutics | 28 | 18% |
| Medical | 18 | 12% |
| Pharmaceutical | 13 | 9% |

14 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 36 | 24% |
| Series B | 31 | 20% |
| Series C | 18 | 12% |
| Funding Round | 10 | 7% |
| Series D | 8 | 5% |

10 stages tracked in total.

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| David Goeddel | Managing Partner | 16 | https://shizune.co/investors/profile/david-v-goeddel |
| Jeff Goater | Venture Partner | 7 | https://shizune.co/investors/profile/dinah-sah-2 |
| Joseph Goldstein | Science Partner | 0 | https://shizune.co/investors/profile/joseph-l-goldstein |
| Millie Ray | Partner | 5 | https://shizune.co/investors/profile/millie-ray |
| Peter Svennilson | Managing Partner and Founder | 16 | https://shizune.co/investors/profile/peter-svennilson |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Nura Bio | Nura Bio revolutionizes the treatment of neurological diseases with novel, life-changing neuroprotective medicines. Nura Bio was conceived in 2018 by The Column Group and its scientific founders. | $73.8M | Series B | Jun 22, 2026 |  |
| Tortugas Neuroscience | Tortugas Neuroscience is a neurology-focused biotech company dedicated to developing effective medicines that address diseases of the brain. | $106M | Series A | Apr 21, 2026 |  |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $40M | Series B | Mar 05, 2026 |  |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $40M | Series B | Mar 05, 2026 |  |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $40M | Series B | Mar 05, 2026 |  |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $120M | Series B | Dec 18, 2025 |  |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $120M | Series B | Dec 18, 2025 |  |
| Atavistik Bio | Atavistik Bio is a biotechnology company that specializes in the discovery and development of precision allosteric small molecules aimed at treating metabolic diseases and cancer. The company aims to revolutionize therapeutic approaches by focusing on selective allosteric therapeutics, which can potentially transform treatment options for seriousdiseases. | $120M | Series B | Dec 18, 2025 |  |
| Tr1x | Tr1x develops cellular therapies intended for the treatment of autoimmune disorders. | $50M | Venture - Series Unknown | Oct 14, 2025 |  |
| NILO Therapeutics | NILO Therapeutics is a biotechnology and therapeutics company. | $101M | Series A | Oct 08, 2025 |  |

10 of 152 investments shown.

## Co-investors
- [Lux Capital](https://shizune.co/investors/profile/lux-capital) — VC Fund, 31 deals together
- [Nextech Invest](https://shizune.co/investors/profile/nextech-invest) — VC Fund, 30 deals together
- [Euclidean Capital](https://shizune.co/investors/profile/euclidean-capital) — VC Fund, 19 deals together
- [Third Rock Ventures](https://shizune.co/investors/profile/third-rock-ventures) — VC Fund, 18 deals together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 17 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 16 deals together

## Similar investors

### Similar industry
- [SOSV](https://shizune.co/investors/profile/sosv) — VC Fund
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [Right Side Capital Management](https://shizune.co/investors/profile/right-side-capital-management) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## Featured in investor lists
- [Biotech Investors](https://shizune.co/investors/biotech-investors)
- [Biotech VC Funds](https://shizune.co/investors/biotech-vc-funds)
- [Biotech Investors in United States](https://shizune.co/investors/biotech-investors-united-states)
- [Biotech VC Funds in United States](https://shizune.co/investors/biotech-vc-funds-united-states)
- [Biotechnology Investors](https://shizune.co/investors/biotechnology-investors)
- [Biotechnology VC Funds](https://shizune.co/investors/biotechnology-vc-funds)

## FAQ

### What does The Column Group invest in?

The Column Group invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 152 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is The Column Group's check size?

The Column Group typically joins rounds of $15M–$102M at Series A, $22M–$120M at Series B and $37M–$120M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds The Column Group participates in.

### How do I contact The Column Group?

Public channels for The Column Group include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at The Column Group?

The team at The Column Group includes David Goeddel (Managing Partner), Jeff Goater (Venture Partner) and Joseph Goldstein (Science Partner), among 18 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co